ClinicalTrials.Veeva

Menu

Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF (IVT-RNFL)

F

Fondation Ophtalmologique Adolphe de Rothschild

Status

Completed

Conditions

Retinal Neovascularization

Treatments

Device: Gonioscopy

Study type

Observational

Funder types

NETWORK

Identifiers

NCT02876198
MMT_2015_41

Details and patient eligibility

About

The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration. It also increases microvascular permeability. If the VEGFs have proven their efficiency in the decrease of choroidal neovascular proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown. Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have an incidence on the loss of retinal nerve fibers.

Enrollment

74 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years old
  • Patients treated with anti-VEGF according to the French summary of product characteristics (SPC)
  • Patients who have been informed of the trial and who are not opposed to participate in the study

Exclusion criteria

  • Patients presenting a retinal condition, including the optic nerve
  • Patients treated with anti-VEGF in both eyes
  • Pregnant women
  • Lack of affiliation to social security or universal health coverage

Trial design

74 participants in 1 patient group

Patients treated with anti-VEGF
Treatment:
Device: Gonioscopy

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems